Artelo Biosciences announced a $9.475 million private sale plan to launch its Solana financial strategy.

SOL-2.02%
PANews, September 9 - Nasdaq-listed company Artelo Biosciences (Nasdaq: ARTL) announced the launch of a public offering of common stock and/or pre-funded warrants, with R.F. Lafferty & Co., Inc. serving as the sole bookrunner.
In addition, Artelo announced a private fundraising plan worth $9.475 million, which will initiate financial strategies based on the Solana blockchain, becoming one of the first companies to adopt Solana cryptocurrency as a core reserve asset.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments